查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1870800

导管溶栓装置市场（依产品类型及最终用户划分）－2025-2032年全球预测

Catheter-Directed Thrombolysis Devices Market by Product Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，导管溶栓装置市场规模将达到 6.9582 亿美元，复合年增长率为 5.38%。

关键市场统计数据
基准年 2024 4.5745亿美元
预计年份：2025年 4.8237亿美元
预测年份 2032 6.9582亿美元
复合年增长率 (%) 5.38%

本书为导管溶栓治疗的临床、营运和商业性动态演变提供了一个清晰权威的框架，这些动态决定了导管溶栓治疗的应用和策略重点。

导管溶栓治疗作为急性血管阻塞的重要治疗方法，在器械设计、影像整合和手术流程优化等方面的进步推动下，不断发展。本执行摘要整合了影响该领域的关键临床、商业性和监管趋势，重点介绍了器材创新、临床实践的变革以及医疗机构和製造商必须应对的操作要求。临床医师越来越重视标靶治疗，以最大限度地提高溶栓效果，同时最大限度地减少全身溶栓药物的暴露，这进一步凸显了器械性能和输送精准度的重要性。

整合影像、分散式诊疗路径和策略伙伴关係如何重塑导管溶栓治疗的设备设计、临床工作流程和竞争优势

导管溶栓领域正经历变革性的转变，其意义远不止于简单的设备升级，还包括医疗服务模式的革新、数位整合以及基于价值的采购。其中一个关键变化是影像、设备控制和手术分析技术的日益融合。更精准的整合将实现溶栓药物的精准给药和再灌注的即时评估，从而有望缩短手术时间并减少后续干预。因此，技术蓝图越来越重视封闭回路型手术支援和资料收集，以指导临床决策和与支付方的沟通。

2025年，关税主导的供应链变化将迫使製造商重组生产、采购和商业策略，以保护利润率和市场准入。

到2025年，美国近期一系列关税政策的累积影响正在改变服务导管溶栓市场的医疗设备製造商的供应链格局和策略采购方式。关税提高了某些进口零件和成品的到岸成本，迫使许多供应商重新评估其采购基础，并加速对近岸外包和国内生产的投资。采购部门目前正在仔细权衡前置作业时间灵活性和合规性之间的利弊，并越来越多地选择多源采购策略来降低单一来源采购的风险。

针对特定细分市场的效能要求和应用路径揭示了产品设计和临床实践如何共同决定临床应用和商业策略。

对产品和终端用户细分的深入理解揭示了导管溶栓生态系统中不同的性能驱动因素和应用障碍。依产品类型划分，市场动态可分为：输注导管（如持续输注和脉衝输注）；机械导管（包括抽吸导管、流变导管和旋转导管）；以及超音波辅助导管（分为增强型超音波和标准型超音波）。每类产品都有其独特的临床应用场景和采购考量：输注系统强调对溶栓剂给药和导管放置的控制；机械装置以牺牲手术速度和增加栓塞风险为代价，减少了溶栓剂的暴露量；超音波辅助平台则以增加系统复杂性和培训要求补偿，承诺更快地溶解血栓。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合即时成像技术以提高导管溶栓手术的准确性
  • 开发用于控制局部溶栓和减少全身暴露的药物释放型导管尖端
  • 扩大超音波辅助导管溶栓术在肺动脉栓塞患者的应用
  • 新型生物浸润导管涂层已获得监管部门核准，优化溶栓率和安全性
  • 整合感测器的智慧导管取得了进展，可提供关于血栓负荷和药物分布的即时回馈
  • 动态导管设计的研究进展旨在改善微流线型设计并加速血栓溶解。
  • 利用人工智慧演算法预测最佳溶栓药物剂量，实现个人化导管插入术

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 导管溶栓装置市场（依产品类型划分）

  • 点滴导管
    • 持续输注
    • 脉衝注射
  • 机械导管
    • 吸管
    • 流变导管
    • 旋转导管
  • 超音波辅助导管
    • 增强超音波
    • 标准超音波

9. 依最终用户分類的导管溶栓装置市场

  • 门诊手术中心
  • 医院
  • 专科诊所

10. 各地区导管溶栓装置市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十一章 导管溶栓装置市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

12. 各国导管溶栓装置市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十三章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Boston Scientific Corporation
    • Medtronic plc
    • Johnson & Johnson
    • Koninklijke Philips NV
    • B. Braun Melsungen AG
    • Cook Medical LLC
    • Terumo Corporation
    • AngioDynamics, Inc.
    • Penumbra, Inc.
    • Teleflex Incorporated
Product Code: MRR-1A1A064C03AA

The Catheter-Directed Thrombolysis Devices Market is projected to grow by USD 695.82 million at a CAGR of 5.38% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 457.45 million
Estimated Year [2025] USD 482.37 million
Forecast Year [2032] USD 695.82 million
CAGR (%) 5.38%

A clear and authoritative framing of the evolving clinical, operational, and commercial dynamics defining catheter-directed thrombolysis adoption and strategic priorities

Catheter-directed thrombolysis continues to evolve as a pivotal intervention for acute vascular occlusions, driven by advances in device design, imaging integration, and procedural workflows. This executive summary synthesizes the critical clinical, commercial, and regulatory dynamics shaping the field, focusing on device innovation, shifting care settings, and the operational requirements that providers and manufacturers must navigate. Clinicians increasingly favor targeted approaches that maximize thrombus resolution while minimizing systemic fibrinolytic exposure, which reinforces the centrality of device-level performance and delivery precision.

Across interventional suites, the interplay between device efficiency and procedural throughput influences adoption curves. Hospitals and specialty clinics demand predictable performance, while ambulatory surgical centers are exploring same-day treatment models that require streamlined protocols and robust safety profiles. In parallel, health economic pressures are prompting procurement teams to scrutinize total cost of care and downstream outcomes, making clinical evidence and real-world performance critical components of adoption strategies.

Regulatory scrutiny and reimbursement considerations are exerting continual influence on product development and commercialization. Developers must balance speed-to-market with rigorous post-market evidence generation to support both clinician confidence and payer engagement. Consequently, strategic alignment between R&D, clinical affairs, and commercial teams becomes a prerequisite for long-term competitiveness. This introduction frames the subsequent analysis, which delves into structural shifts, tariff-driven supply chain implications, segmentation nuances, regional performance vectors, competitive behavior, and practical recommendations for market leaders.

How integrated imaging, decentralized care pathways, and strategic partnerships are reshaping device design, clinical workflows, and competitive moats in catheter-directed thrombolysis

The landscape of catheter-directed thrombolysis is undergoing transformative shifts that extend well beyond discrete device upgrades to encompass care delivery models, digital integration, and value-based procurement. One major change is the growing convergence of imaging, device control, and procedural analytics. Enhanced integration permits precise targeting of thrombolytic delivery and real-time assessment of reperfusion, which in turn supports shorter procedures and potentially fewer follow-up interventions. As a result, technology roadmaps increasingly prioritize closed-loop procedural support and data capture to inform both clinical decision-making and payer conversations.

Another critical trend is the decentralization of vascular care. Ambulatory settings and specialty clinics are expanding their procedural portfolios, demanding devices that are intuitive, have reduced accessory requirements, and can be deployed with smaller care teams. This operational shift necessitates new training paradigms and redefined value propositions for manufacturers, who must demonstrate ease of use alongside clinical efficacy. Meanwhile, device developers are accelerating modularization and platform strategies so that incremental innovations can be introduced without full-system replacements, thereby preserving installed-base relationships and smoothing upgrade cycles.

Finally, cross-sector partnerships are reshaping competitive dynamics. Collaborations between device OEMs, imaging companies, and digital health firms are enabling bundled solutions that emphasize outcome tracking and procedural optimization. These alliances are creating higher barriers to entry for single-product suppliers and rewarding firms that can offer integrated clinical workflows. Taken together, these transformative shifts require stakeholders to prioritize interoperability, training, and evidence generation to secure long-term relevance.

How tariff-driven supply chain shifts through 2025 are forcing manufacturers to reconfigure production, sourcing, and commercial strategies to protect margin and access

The cumulative impact of recent tariff policies in the United States through 2025 has altered supply chain calculus and strategic sourcing for device manufacturers serving the catheter-directed thrombolysis market. Tariffs have increased the landed cost of certain imported components and finished goods, prompting many suppliers to reassess their sourcing footprints and to accelerate nearshoring or domestic manufacturing investments. Procurement teams now weigh the trade-offs between unit cost, lead-time resilience, and regulatory compliance, often selecting multi-sourcing strategies to mitigate single-origin risk.

In response to tariff-driven cost pressures, manufacturers have pursued process and product-level optimizations to preserve margin while maintaining clinical performance. These adjustments include greater use of local contract manufacturing organizations for final assembly, reengineering of packaging to reduce freight volumetrics, and negotiation of longer-term supplier agreements to stabilize input pricing. Concurrently, some companies have adopted hedging strategies and pricing clauses that pass a portion of increased input costs through to purchasers, while others have absorbed costs temporarily to maintain competitive positioning.

From a market access perspective, tariff effects have influenced device lifecycle decisions, such as prioritizing higher-margin product lines for domestic production and postponing lower-margin variants that are more exposed to import costs. In addition, tariff uncertainty has elevated the importance of scenario planning within commercial strategies, with firms building flexible go-to-market playbooks that can adapt to sudden cost shifts. Ultimately, the tariff environment through 2025 has reinforced the strategic value of supply chain transparency, nimble manufacturing, and close collaboration across procurement, regulatory, and commercial functions to protect access and sustain innovation.

Segment-specific performance imperatives and adoption pathways reveal how product architecture and care settings jointly determine clinical uptake and commercial playbooks

A granular understanding of product and end-user segmentation reveals differentiated performance drivers and adoption barriers across the catheter-directed thrombolysis ecosystem. Based on Product Type, market dynamics diverge between Infusion Catheter variants such as Continuous Infusion and Pulsatile Infusion, Mechanical Catheter subtypes including Aspiration Catheter, Rheolytic Catheter, and Rotational Catheter, and Ultrasound-Assisted Catheter categories split into Enhanced Ultrasound and Standard Ultrasound. Each product class presents unique clinical use-cases and procurement considerations: infusion-based systems emphasize controlled lytic delivery and catheter dwell characteristics; mechanical devices trade off procedural speed and embolic risk for reduced lytic exposure; and ultrasound-enabled platforms promise faster thrombus disruption at the cost of additional system complexity and training demands.

Based on End User, adoption pathways differ across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, with each setting imposing distinct requirements on device usability, inventory management, and ancillary services. Hospitals typically demand devices that fit into complex care pathways, offering comprehensive training support, service contracts, and immediate technical escalation. Specialty clinics value targeted performance attributes and streamlined reimbursement support, while ambulatory surgical centers prioritize devices that minimize procedure time, reduce post-procedural monitoring, and support same-day discharge. These differences influence product design priorities and commercial tactics, such as bundled offering development, clinical training programs, and flexible financing structures.

Transitioning from segmentation to execution, manufacturers should align clinical evidence generation and customer engagement with the unique requirements of each product subtype and end-user setting. By mapping clinical workflows to device capabilities and reimbursement pathways, organizations can craft differentiated value narratives and targeted adoption pilots that demonstrably address provider pain points while minimizing operational friction.

How regional regulatory complexity, payer heterogeneity, and capacity expansion shape differentiated market access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a profound influence on device development priorities, regulatory strategy, and commercial deployment, with the Americas, Europe, Middle East & Africa, and Asia-Pacific each presenting distinct vectors of opportunity and constraint. In the Americas, strong hospital networks, established interventional specialist communities, and relatively rapid adoption of minimally invasive therapies support early uptake of advanced thrombolysis platforms. However, heterogeneity in payer reimbursement policies and the increasing emphasis on value-based contracting require manufacturers to present robust clinical and health economic evidence to secure preferred positioning with large hospital systems.

Europe, Middle East & Africa encompasses a wide spectrum of regulatory regimes and procurement approaches, where centralized reimbursement decisions in some jurisdictions coexist with hospital-level purchasing practices in others. This regional complexity necessitates adaptive market access strategies, such as modular clinical programs that can be calibrated to local evidence requirements and commercial partnerships that extend reimbursement support and clinician training. In contrast, Asia-Pacific is characterized by rapid capacity expansion, an expanding interventionalist workforce, and intense price sensitivity in several markets. Manufacturers seeking traction in APAC often combine tiered pricing models with local training initiatives and selective manufacturing partnerships to meet cost and regulatory demands.

Across all regions, cross-border coordination of clinical evidence, post-market surveillance, and supply chain resilience is critical. Firms that can harmonize global regulatory submissions, while tailoring real-world evidence collection and pricing approaches to regional specifics, are better positioned to scale adoption efficiently and to manage the operational complexity inherent in multi-regional rollouts.

Why successful companies combine platform-level innovation, evidence generation, and integrated services to build durable competitive advantage in thrombolysis therapies

Competitive dynamics among firms active in catheter-directed thrombolysis are increasingly defined by a blend of clinical differentiation, systems-level integration, and strategic partnerships. Leading developers have shifted from offering singular catheter products to providing ecosystem plays that include imaging integration, procedural analytics, and service packages designed to shorten learning curves and improve outcomes. This movement elevates the importance of breadth in clinical data, multi-center real-world evidence, and the capability to support intensive training programs that de-risk adoption for health systems.

Acquisitions and licensing deals are commonplace as companies seek to augment technical portfolios with complementary technologies such as ultrasound energy delivery, advanced infusion control, or thrombectomy modalities. Firms that have invested early in platform architectures gain an advantage because modular upgrades can be introduced with less disruption to existing customers, fostering stickiness and recurring revenue through consumables and service agreements. At the same time, agile smaller companies often drive innovation in niche product features and can influence clinical practice when their solutions demonstrably reduce procedure time or complication rates.

From a go-to-market perspective, successful companies combine clinical and economic narratives. They articulate not only improvements in vessel patency and procedural efficiency but also measurable reductions in length of stay, readmission risk, and adverse event rates. Those that collaborate closely with key opinion leaders to publish outcomes and to design pragmatic training curricula tend to accelerate clinician trust and adoption. To preserve competitive advantage, leading firms are investing in post-market surveillance systems and outcome registries that continually reinforce product value and inform iterative design enhancements.

Practical and prioritized actions for executives to convert technical differentiation into commercial scale through interoperability, resilient supply chains, and targeted evidence generation

Industry leaders should pursue a set of coordinated actions that translate device-level advantages into sustainable commercial outcomes. First, prioritize interoperable product architectures that enable rapid integration with imaging and data systems, thereby creating procedural efficiencies and facilitating outcome measurement. Investing in modular platforms reduces upgrade friction for existing customers and creates recurring revenue opportunities through consumables and service contracts. Second, align clinical affairs, regulatory, and reimbursement teams to develop targeted evidence packages for prioritized segments and regions; evidence that demonstrates both clinical benefit and downstream economic value will materially improve procurement conversations with health systems.

Third, strengthen supply chain resilience through dual sourcing, regional manufacturing partnerships, and transparent inventory analytics to mitigate tariff and logistics risks. This reduces vulnerability to input-cost shocks and supports reliable customer delivery timelines. Fourth, deploy differentiated commercial models that reflect end-user needs-hospitals require comprehensive training and service support, specialty clinics value streamlined deployment and cost predictability, and ambulatory surgical centers seek devices that enable same-day pathways. Tailored pricing, financing, and training packages will accelerate adoption across these settings.

Finally, commit to collaborative partnerships with clinical centers for real-world evidence generation and procedural optimization. These collaborations should target clinical outcome registries and pragmatic trials that inform continuous product improvements and strengthen payer engagement. By executing on these priorities with discipline, industry leaders can convert technological innovation into measurable improvements in patient outcomes and durable market positions.

A rigorous mixed-methods research approach combining clinical expert interviews, regulatory mapping, and supply chain analysis to validate strategic insights for decision-makers

This analysis is grounded in a mixed-methods research approach that synthesizes primary stakeholder interviews, device labeling and regulatory documentation, peer-reviewed clinical literature, and a structured review of company disclosures and clinical registries. Primary engagement included interviews with interventional specialists, procurement leaders, and clinical affairs executives to capture contemporary decision drivers and procedural trends. These qualitative insights were triangulated with an analysis of device indications, procedural protocols, and published outcome data to ensure clinical assertions are supported by evidence.

Supplementing qualitative inputs, the methodology incorporated a structured assessment of supply chain footprints, tariff exposures, and manufacturing options based on publicly available trade and customs data. Regional regulatory frameworks were mapped against device classification and pre-market pathways to identify typical requirements and potential accelerators for market entry. Additionally, competitive behavior was examined through disclosures, patent filings, and partnership announcements to identify strategic patterns such as platform expansion, vertical integration, and service-oriented monetization.

Throughout the research process, rigorous validation practices were applied. Key findings and interpretations were subjected to expert review and iterative refinement with clinical and commercial advisors. Where appropriate, sensitivity to regional heterogeneity and clinical practice variation was maintained to avoid overgeneralization. This methodological rigor supports both the credibility of the insights presented and their applicability to practical strategy development.

A synthesis of clinical, commercial, and operational imperatives that clarifies how organizations should align investment, evidence, and supply chains to win in thrombolysis

In conclusion, catheter-directed thrombolysis is at an inflection point where device innovation, care-setting decentralization, and value-driven procurement intersect to redefine market trajectories. The interplay between product architecture and end-user requirements necessitates focused evidence generation and differentiated commercial approaches. Meanwhile, external pressures such as tariffs and regional regulatory diversity are reshaping supply chains and product prioritization, underscoring the need for resilient manufacturing and flexible sourcing strategies.

Manufacturers that invest in interoperable platforms, build compelling health economic narratives, and pursue pragmatic partnerships with clinical centers will be best positioned to capture long-term value. Likewise, commercial leaders must tailor propositions to the distinct operational realities of hospitals, specialty clinics, and ambulatory surgical centers, while maintaining the agility to adapt to regional nuances. Ultimately, success will rest on the ability to translate technical improvements into demonstrable clinical outcomes and measurable reductions in total cost of care, thereby answering the practical questions that payers and providers pose during procurement.

This executive summary is intended to inform strategic planning, guide prioritization of R&D and market access investments, and support alignment across clinical, regulatory, and commercial functions so that organizations can confidently navigate the evolving landscape and accelerate adoption of best-in-class thrombolysis solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of real-time imaging modalities to enhance precision in catheter-directed thrombolytic procedures
  • 5.2. Development of drug-eluting catheter tips for controlled localized thrombolytic delivery and reduced systemic exposure
  • 5.3. Increasing adoption of ultrasound-facilitated catheter-directed thrombolysis in treatment of pulmonary embolism patients
  • 5.4. Regulatory approvals for novel biologic-laden catheter coatings to optimize clot dissolution rates and safety profiles
  • 5.5. Advancements in sensor-integrated smart catheters for real-time feedback on thrombus burden and drug dispersion
  • 5.6. Growing research into hydrodynamic catheter designs to improve microstreamlining and accelerate clot lysis
  • 5.7. Incorporation of AI algorithms to predict optimal thrombolytic dosing and personalize catheter-directed therapy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Catheter-Directed Thrombolysis Devices Market, by Product Type

  • 8.1. Infusion Catheter
    • 8.1.1. Continuous Infusion
    • 8.1.2. Pulsatile Infusion
  • 8.2. Mechanical Catheter
    • 8.2.1. Aspiration Catheter
    • 8.2.2. Rheolytic Catheter
    • 8.2.3. Rotational Catheter
  • 8.3. Ultrasound-Assisted Catheter
    • 8.3.1. Enhanced Ultrasound
    • 8.3.2. Standard Ultrasound

9. Catheter-Directed Thrombolysis Devices Market, by End User

  • 9.1. Ambulatory Surgical Centers
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Catheter-Directed Thrombolysis Devices Market, by Region

  • 10.1. Americas
    • 10.1.1. North America
    • 10.1.2. Latin America
  • 10.2. Europe, Middle East & Africa
    • 10.2.1. Europe
    • 10.2.2. Middle East
    • 10.2.3. Africa
  • 10.3. Asia-Pacific

11. Catheter-Directed Thrombolysis Devices Market, by Group

  • 11.1. ASEAN
  • 11.2. GCC
  • 11.3. European Union
  • 11.4. BRICS
  • 11.5. G7
  • 11.6. NATO

12. Catheter-Directed Thrombolysis Devices Market, by Country

  • 12.1. United States
  • 12.2. Canada
  • 12.3. Mexico
  • 12.4. Brazil
  • 12.5. United Kingdom
  • 12.6. Germany
  • 12.7. France
  • 12.8. Russia
  • 12.9. Italy
  • 12.10. Spain
  • 12.11. China
  • 12.12. India
  • 12.13. Japan
  • 12.14. Australia
  • 12.15. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Analysis
    • 13.3.1. Boston Scientific Corporation
    • 13.3.2. Medtronic plc
    • 13.3.3. Johnson & Johnson
    • 13.3.4. Koninklijke Philips N.V.
    • 13.3.5. B. Braun Melsungen AG
    • 13.3.6. Cook Medical LLC
    • 13.3.7. Terumo Corporation
    • 13.3.8. AngioDynamics, Inc.
    • 13.3.9. Penumbra, Inc.
    • 13.3.10. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 97. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 160. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 198. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 203. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 210. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 211. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 212. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 213. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 214. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 215. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 234. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 235. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 236. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 237. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 238. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 239. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 246. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 247. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 248. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 249. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 250. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 251. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 258. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 259. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 260. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 261. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 262. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2025-2032 (USD MILLION)
  • TABLE 263. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2025-2032 (USD MILLION)
  • TABLE 271. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2025-2032 (USD MILLION)
  • TABLE 273. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRA